The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions
- 1 July 2018
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (4) , 1287-1296.e1
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- In vitro drug causality assessment in Stevens–Johnson syndrome – alternatives for lymphocyte transformation testClinical & Experimental Allergy, 2013
- Amikacin-induced drug reaction with eosinophilia and systemic symptoms syndrome: Delayed skin test and ELISPOT assay results allow the identification of the culprit drugJournal of Allergy and Clinical Immunology, 2012
- Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic FibrosisThe Journal of Pharmacology and Experimental Therapeutics, 2012
- High‐avidity, high‐IFNγ‐producing CD8 T‐cell responses following immune selection during HIV‐1 infectionImmunology & Cell Biology, 2011
- Stimulation of human T cells with sulfonamides and sulfonamide metabolitesJournal of Allergy and Clinical Immunology, 2010
- Detection and quantification of drug‐specific T cells in penicillin allergyAllergy, 2009
- Mast cell–derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet BNature Immunology, 2007
- Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactionsJournal of Allergy and Clinical Immunology, 2006
- IFN-γ–producing effector CD8+ T cells and IL-10–producing regulatory CD4+ T cells in fixed drug eruptionJournal of Allergy and Clinical Immunology, 2003
- Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactionsContact Dermatitis, 2001